Interim guidelines for health facilities in transition to the endemic phase of COVID-19

Reiteration of the PhilHealth benefit packages for inpatient management of confirmed Coronavirus Disease (COVID-19) and clarification of coverage of probable cases

Further amendment to DC 2021-0464 entitled “Interim operational guidelines on the COVID-19 vaccination of pediatric population ages 12-17 years old with comorbidities”

Amendment to DC 2021-0483 entitled “Interim operational guidelines on the COVID-19 vaccination of the rest of the pediatric population ages 12-17 years old”

Guidelines on the grant of one COVID-19 allowance (OCA) to Public and Private Health Care Workers (HCWs) and Non-HCW’s in health facilities involved in COVID-19 response

Amendment to DM No. 2022-0041 dated January 24, 2022 entitled “Interim Guidelines on the management and administration of Tozinameran COVID-19 mRNA vaccine (nucleoside-modified) [Comirnaty] Pfizer COVID-19 vaccine to pediatric population ages 5-11 y/o

Guidelines on the use of self-administered antigen testing for COVID-19

Interim guidelines on the management and administration of Tozinameran COVID-19 mRNA vaccine (nucleoside-modified) [Cominarty] Pfizer COVID-19 vaccine to pediatric population ages 5-11 years old

Operational Guidelines for the Loaning of COVID-19 Vaccine Doses Between the National Government, Local Government Units, and Private Sector Entities

Adjustments in Maximum Retail Price (MRP) regulation of certain medicines that are covered by Executive Order No. 155 pursuant to exemption from Value Added Tax (VAT)

Updated Guidelines on Quarantine, Isolation, and Testing for COVID-19 Response and Case Management for the Omicron Variant

Setting of purchase limit/cap for Paracetamol, Phenylephrinehydochloride, Carbocisteine, and Chlorphenamine Maleate Paracetamol